Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A tripeptide (Lysine-Proline-Valine) derived from the C-terminus of alpha-MSH (melanocyte-stimulating hormone). Has potent anti-inflammatory properties and is being studied for inflammatory bowel conditions and wound healing.
A synthetic 15-amino acid peptide derived from a protective protein found in human gastric juice. One of the most widely researched peptides for tissue repair and recovery.
Inhibits NF-κB signaling and pro-inflammatory cytokine production. Crosses the intestinal epithelium to directly suppress inflammation locally. Anti-microbial properties have also been demonstrated in vitro.
BPC-157 promotes angiogenesis (new blood vessel formation), upregulates growth factor expression, and modulates nitric oxide synthesis. It appears to accelerate healing of tendons, ligaments, muscles, and the GI tract through multiple pathways including the FAK-paxillin pathway.
- Inflammatory bowel disease (IBD) support
- Wound healing and skin conditions
- General anti-inflammatory protocols
- Gut health optimization
- Tendon and ligament repair
- Gut healing and GI protection
- Muscle injury recovery
- Joint health
- Post-surgical recovery
- Very limited human clinical data
- Optimal delivery method not established
- Injection vs. oral bioavailability differences not fully characterized
- Long-term safety unknown
- Limited human clinical trial data
- Most research is animal-based
- Potential interactions with blood pressure medications
- Injection site reactions
- Long-term safety profile unknown
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 23, 2026 for wound healing and inflammatory conditions. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 23, 2026
On April 15, 2026, the FDA announced BPC-157 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. It is now scheduled for formal PCAC (Pharmacy Compounding Advisory Committee) review on July 23, 2026, to determine whether it should be added to the 503A bulk drug substances list. Removal from Category 2 does not authorize compounding — pharmacies should exercise caution until PCAC issues its recommendation. Previously reclassified to Category 1 in February 2026, a step that is now superseded by this more formal process.
PCAC: July 23, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.